- Home
- RELL vs ZNTL Comparison
RELL vs ZNTL Comparison
Compare RELL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RELL | ZNTL |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.0M | 156.7M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RELL | ZNTL |
|---|---|---|
| Price | $11.00 | $2.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 118.4K | ★ 665.7K |
| Earning Date | 04-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,909,000.00 | $67,425,000.00 |
| Revenue This Year | $5.62 | N/A |
| Revenue Next Year | $13.95 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ 6.34 | N/A |
| 52 Week Low | $7.57 | $1.01 |
| 52 Week High | $15.34 | $3.95 |
Technical Indicators
Market Signals| Indicator | RELL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 53.72 |
| Support Level | $10.49 | $1.29 |
| Resistance Level | $11.38 | $2.69 |
| Average True Range (ATR) | 0.75 | 0.22 |
| MACD | -0.23 | 0.04 |
| Stochastic Oscillator | 11.97 | 47.92 |
Price Performance
Historical ComparisonAbout RELL Richardson Electronics Ltd.
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.